Articles On Paradigm Biopharmaceuticals (ASX:PAR)
Title | Source | Codes | Date |
---|---|---|---|
ASX set to close higher on tech rally, gets a boost from robust sales data
Summary The ASX 200 is set to close the week with narrow gains, led by a strong rally in healthcare and tech stocks. The top five gainers on the ASX are EML Payments, A2 Milk Company, Webjet, Nuix and Xero. Bitcoin staged a smart reco... |
Kalkine Media | PAR | 2 years ago |
ASX reclaims 7000 mark on financial, tech boost; Afterpay jumps 7%
Summary The ASX 200 gained 89.50 points or 1.29% to 7021.20 amid broad-based buying. Nine of the 11 sectors traded in the green, while tech stocks lead the pack with a 4.32% gain. Afterpay emerges as the top gainer, followed by Redbu... |
Kalkine Media | PAR | 2 years ago |
Paradigm Biopharmaceuticals secures first revenues for Zilosul
|
Proactive Investors | PAR | 2 years ago |
ASX records worst performance in three months; EML Payments crashes 45%
Summary The ASX 200 is heading towards its worst performance since late February, down 2% at 6924.10 at the close. The market breadth was extremely week, with all the 11 sectoral indices trading in red. EML Payments shares plunged ove... |
Kalkine Media | PAR | 2 years ago |
Paradigm Biopharmaceuticals achieves first revenue via Zilosul® prescription under the TGA Special Access Scheme
Under the pay-for-use SAS program, Paradigm has already received five prescriptions for Zilosul® from physicians and the five patients will commence Zilosul® treatment in the coming week. |
Proactive Investors | PAR | 2 years ago |
Three ASX healthcare stocks that are trending today – ILA, 1AD and PAR
Summary Island Pharmaceuticals and AdAlta have obtained patent protection for their lead programs in the US and Japan, respectively. Paradigm Biopharmaceuticals has received first revenue through a physician prescription of Zilosul®.... |
Kalkine Media | PAR | 2 years ago |
Why Appen, ELMO, Nuix, & Paradigm shares are pushing higher
In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 1.8% to 6,937.6 points. Four ASX shares that haven’t let that hold them back... |
Motley Fool | PAR | 2 years ago |
ASX 200 today: Why market is on track to mark worst session since February
Summary The Australian shares opened lower on Wednesday after rising in the last three sessions. The domestic equity benchmark ASX 200 opened lower by 17.60 points or 0.25% to 7,048.40. The benchmark traded in the negative zon... |
Kalkine Media | PAR | 2 years ago |
Why Bubs, Carbon Revolution, Paradigm, & Tyro shares are sinking
In afternoon trade on Monday, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a small decline. At the time of writing, the benchmark index is down slightly to 7,057.7 points. Four ASX shares that are falling more t... |
Motley Fool | PAR | 3 years ago |
Paradigm (ASX:PAR) share price drops on drug application update
The share price of Paradigm Biopharmaceuticals Ltd (ASX: PAR) is down today on an update of its new drug application. What does this mean for the Paradigm share price? Paradigm has repurposed an anti-inflammatory drug called pentosan polysu... |
Rask Media | PAR | 3 years ago |
Why the Paradigm (ASX:PAR) share price is sinking 5% today
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has started the week in the red. In morning trade, the clinical stage biopharmaceutical company’s shares are down just under 5% to $2.44. Why is the Paradigm share price sinking lo... |
Motley Fool | PAR | 3 years ago |
Paradigm Biopharmaceuticals progresses IND application with US FDA for knee OA treatment
The FDA was unable to provide all questions within the initial IND review period and has advised it will submit further questions to Paradigm within the next 30 days. |
Proactive Investors | PAR | 3 years ago |
Paradigm Biopharmaceuticals updates as first patient dosed in knee osteoarthritis study
|
Proactive Investors | PAR | 3 years ago |
Paradigm Biopharmaceuticals doses first participant in Para_OA_008 clinical trial exploring knee OA synovial biomarkers
The study will investigate changes in knee synovial fluid biomarkers associated with pain, inflammation and disease progression of knee Osteoarthritis. |
Proactive Investors | PAR | 3 years ago |
Why the Paradigm (ASX:PAR) share price is charging higher today
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has been a positive performer on Wednesday. In morning trade, the biopharmaceutical company’s shares are up 3% to $2.65. Why is the Paradigm share price charging higher? Investors... |
Motley Fool | PAR | 3 years ago |
Uranium explorer 92 Energy eyes ASX listing for mid-April
Uranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or next week after bioenergy company Delorean joined the bourse yesterday. There are four IPOs timed for this week, including Delorean (ASX: DE... |
Stockhead | PAR | 3 years ago |
Here’s why Paradigm (ASX:PAR) & Opthea (ASX:OPT) shares are on watch
Source:Ratanapon Srisuneton, Shutterstock Summary Opthea gets an iPSP waiver from the FDA for its lead product candidate to treat wet AMD. Paradigm and bene pharmaChem set to collaborate for the development of iPPS and other formulati... |
Kalkine Media | PAR | 3 years ago |
Paradigm (ASX:PAR) share price rises on partnership news
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is on the rise this morning following a partnership agreement. At the time of writing, the biopharmaceutical company’s shares are up 1.92% to $2.66. What did Paradigm announce? Par... |
Motley Fool | PAR | 3 years ago |
Why these 2 ASX-listed healthcare companies are hogging limelight?
Source: Source: janews , Shutterstock Healthcare takes over 1/10th per cent of the GDP of the most developed countries and the US contributes the most to this industry. As the coronavirus pandemic hit hard every industry, including hea... |
Kalkine Media | PAR | 3 years ago |
Paradigm Biopharmaceuticals Shares Up on IND Application (ASX:PAR)
The Paradigm Biopharmaceuticals Ltd [ASX:PAR] share price is up more than 4%, trading at $2.51. The PAR share price has largely traded sideways since October... The post Paradigm Biopharmaceuticals Shares Up on IND Application (ASX:PAR) app... |
MoneyMorning | PAR | 3 years ago |
Why Galaxy, HUB24, Paradigm, & Telstra shares are pushing higher
In afternoon trade the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is pushing higher. At the time of writing, the benchmark index is up 0.45% to 6,820.8 points. Four ASX shares that are climbing more than most... |
Motley Fool | PAR | 3 years ago |
Why the Paradigm (ASX:PAR) share price is charging 6% higher today
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is charging higher on Friday. In early afternoon trade the biopharmaceutical company’s shares are up a sizeable 6% to $2.55. Why is the Paradigm share price charging higher today?... |
Motley Fool | PAR | 3 years ago |
Why is the Paradigm (ASX:PAR) share price climbing today?
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price gained ground today and is presently trading at $2.55 a share, a 2.82% bounce. The share price increase comes after Paradigm released its 1HY21 financial results. Here’s the rundow... |
Motley Fool | PAR | 3 years ago |
Paradigm Biopharmaceuticals boosts finances with $3.38 million R&D tax refund from Australian Government
Paradigm is a late-stage drug development company with the mission to develop and commercialise Pentosan Polysulfate Sodium for the treatment of pain associated with musculoskeletal disorders driven by injury and inflammation. |
Proactive Investors | PAR | 3 years ago |
Paradigm Biopharmaceuticals receives ethics approval for Phase 2 clinical trial of PPS in knee osteoarthritis pain
The Phase 2 study will evaluate the treatment effect of Pentosan Polysulfate Sodium (PPS) (Zilosul®) compared with placebo on synovial fluid biomarkers in participants with knee osteoarthritis pain. |
Proactive Investors | PAR | 3 years ago |
Paradigm Biopharmaceuticals appoints new non-executive director to support commercialisation plans
The company continues to progress toward submission of the investigational new drug for Zilosul® and is focused on implementation of the osteoarthritis clinical program to support commercialisation. |
Proactive Investors | PAR | 3 years ago |
Paradigm Biopharmaceuticals Shares Riding High on Significant OA Treatment Data
Summary ASX 300-listed Paradigm Biopharmaceuticals disclosed ongoing data for Zilosul® treatment under the SAS. The drug development player is firmly focused on the IND submission for its OA treatment this quarter. Paradigm also highl... |
Kalkine Media | PAR | 3 years ago |
Why the Paradigm (ASX:PAR) share price is jumping higher today
It has been a positive day of trade for the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price. In morning trade, the biopharmaceutical company’s shares jumped 8% higher to $2.70. Why did the Paradigm share price jump higher? The catal... |
Motley Fool | PAR | 3 years ago |
Paradigm Biopharmaceuticals' additional data on Zilosul® patients under the TGA SAS shows very consistent reduction in pain of nearly 50%
In the 89 patients treated with Zilosul®, 75.3% reported at least a 25% reduction in WOMAC pain with 56.2% of patients reporting a greater than 50% reduction, while in subjects with knee OA, it shows a very consistent reduction in pain of n... |
Proactive Investors | PAR | 3 years ago |
Invex Therapeutics pushes on with phase three trial design to repurpose drug for brain disorder
Invex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use a diabetic drug for a neurological condition in desperate need for treatment. The biopharmaceutical company is focused on repurposing the d... |
SmallCaps | PAR | 3 years ago |
Paradigm Biopharmaceuticals lays out roadmap for the future at JP Morgan Healthcare Conference
Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive. |
Proactive Investors | PAR | 3 years ago |
Paradigm Biopharmaceuticals lays out roadmap for the future at JP Morgan Healthcare Conference
Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive. |
Proactive Investors | PAR | 3 years ago |
Why the Paradigm (ASX:PAR) share price is jumping higher
Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are jumping higher today after the company provided an update prior to market open this morning. At the time of writing, the Paradigm share price is trading 1.2% higher at $2.50. What’s dri... |
Motley Fool | PAR | 3 years ago |
Paradigm shifts focus to IND after getting FDA’s positive response for OA treatment
Summary ASX-300 Paradigm Biopharmaceuticals has obtained FDA’s response in favour of its OA treatment. The Company is finalising to submit IND to the FDA during Q1 CY2021. Paradigm has commenced preliminary work for its Phase 3 clinic... |
Kalkine Media | PAR | 3 years ago |
Why Mesoblast, Paradigm, Qantas, & QBE shares are tumbling lower
The S&P/ASX 200 Index (ASX: XJO) looks set to end the week in a disappointing fashion. In late morning trade the benchmark index is down a sizeable 0.75% to 6,706.3 points. Four shares that have fallen more than most today are listed b... |
Motley Fool | PAR | 3 years ago |
Why the Paradigm (ASX:PAR) share price is pushing higher today
In morning trade the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is climbing higher. At the time of writing, the biopharmaceutical company’s shares are up 2% to $2.59. Why is the Paradigm share price rising? Investors have been... |
Motley Fool | PAR | 3 years ago |
Paradigm Biopharmaceuticals proceeding with IND submission for Zilosul® for osteoarthritis after positive FDA Type C meeting feedback
The same clinical trial protocol will be used in the US, Europe and Australia, potentially enabling registrations in multiple jurisdictions, saving time and money. |
Proactive Investors | PAR | 3 years ago |
Paradigm (ASX:PAR) share price drops lower on trial update
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has come under pressure on Monday morning following the release of an update on its osteoarthritis (OA) clinical program. At the time of writing, the late stage drug development co... |
Motley Fool | PAR | 3 years ago |
Paradigm Biopharmaceuticals adds IP expertise to board with Amos Meltzer appointed non-executive director
The company is continuing the search for a person with extensive financial experience who will also be added to the board as an independent non-executive director. |
Proactive Investors | PAR | 3 years ago |
Paradigm Biopharmaceuticals to host first R&D presentation this month to update on Zilosul pipeline
The late-stage drug development company said the presentation would cover its proposed clinical program, safety and an update on other indications in the company’s R&D pipeline. |
Proactive Investors | PAR | 3 years ago |
Paradigm Biopharmaceuticals (ASX:PAR) commences MPS-I Phase 2 trial, first patient dosed
Summary ASX 300-listed Paradigm Biopharmaceuticals has started its Mucopolysaccharidosis type I (MPS-I) open-label Phase 2 clinical trial. The trial will assess the safety and tolerability of iPPS in MPS-I patients and will be conducted... |
Kalkine Media | PAR | 3 years ago |
Why the Paradigm (ASX:PAR) share price is climbing higher today
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is climbing higher today on news the company has started Phase 2 trials of pentosan polysulphate sodium (iPPS). In early morning trade, the Paradigm share price is up 1.62% to $3.1... |
Motley Fool | PAR | 3 years ago |
Paradigm Biopharmaceuticals initiates Mucopolysaccharidosis type I open label Phase II clinical trial with first patient dosed
The trial will be Paradigm’s first in MPS-I patients and will investigate treatment in a population, including pediatric patients. |
Proactive Investors | PAR | 3 years ago |
Paradigm Biopharmaceuticals adds three new senior executives to its team
Commercial head Beverley Huttmann, chief financial officer Justin Cahill and R&D scientist Catherine Stapledon bring skills and experience that further strengthen the capabilities of management as the company moves toward commercialisat... |
Proactive Investors | PAR | 3 years ago |
Paradigm Biopharmaceuticals’ Announces Positive Data on its Phase 3 Product Zilosul®; Share Price Soared ~8%
Summary ASX 300 player Paradigm Biopharmaceuticals has reported additional positive data on patients who received Zilosul® under the Special Access Scheme (SAS) of the TGA. The Company anticipates providing information on further patien... |
Kalkine Media | PAR | 3 years ago |
Paradigm Biopharmaceuticals data shows Zilosul reduces pain in patients with knee osteoarthritis
Pain reduction in 76 SAS patients (42 new patient data) being treated using the Phase 3 product are consistent with prior reports under TGA SAS. |
Proactive Investors | PAR | 3 years ago |
Why BHP, Paradigm, Reliance, & SeaLink shares are charging higher today
In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to bounce back strongly from yesterday’s surprise selloff. At the time of writing the benchmark index is up 1.35% to 5,894.3 points. Four shares that are climbing more... |
Motley Fool | PAR | 3 years ago |
Paradigm Biopharmaceuticals (ASX:PAR) reports Zilosul reduces pain in knee patients
01 Oct 2020 - Paradigm Biopharmaceuticals (ASX:PAR) report that patients receiving Zilosul reported a reduction in pain. |
FNN | PAR | 3 years ago |
Paradigm (ASX:PAR) share price rockets higher on Zilosul update
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is charging higher again on Thursday. In morning trade the biopharmaceutical company’s shares are up a sizeable 9% to $2.89. This latest gain means the Paradigm share price is now... |
Motley Fool | PAR | 3 years ago |
ASX 300 Paradigm Biopharmaceuticals’ Share Price On Watch Post Key Announcements
Summary Paradigm Biopharmaceuticals’ supply agreement & exclusive licence with bene pharmaChem has been amended with positive & material commercial outcomes for bene pharmaChem is the only Pentosan Polysulphate Sodium (PPS) manuf... |
Kalkine Media | PAR | 3 years ago |